393 related articles for article (PubMed ID: 9781955)
1. Pleural effusion in patients with non-Hodgkin's lymphoma: a case-controlled study.
Elis A; Blickstein D; Mulchanov I; Manor Y; Radnay J; Shapiro H; Lishner M
Cancer; 1998 Oct; 83(8):1607-11. PubMed ID: 9781955
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
3. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
Bai CM; Yang T; Xü Y; Zhang W; Liu XL; Zhu YL; Chen SC; Shen T
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):142-4. PubMed ID: 16750023
[TBL] [Abstract][Full Text] [Related]
7. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and prognostic value of pleural effusions in non-Hodgkin's lymphomas.
Xaubet A; Diumenjo MC; Maŕin A; Montserrat E; Estopá R; Llebaría C; Austí A; Rozman C
Eur J Respir Dis; 1985 Feb; 66(2):135-40. PubMed ID: 3882444
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
11. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.
Atra A; Imeson JD; Hobson R; Gerrard M; Hann IM; Eden OB; Carter RL; Pinkerton CR
Br J Cancer; 2000 Apr; 82(8):1396-402. PubMed ID: 10780517
[TBL] [Abstract][Full Text] [Related]
13. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
14. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
17. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
[TBL] [Abstract][Full Text] [Related]
19. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
20. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]